Plogosertib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Leukemia. According to GlobalData, Phase II drugs for Leukemia have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Plogosertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Plogosertib overview

Plogosertib is under development for the treatment of solid tumors including triple negative breast cancer, esophageal cancer, colorectal cancer, myelodysplastic syndrome and blood cancer including chronic lymphoblastic leukemia (CLL), relapsed/refractory acute myeloblastic leukemia, relapsed/refractory leukemias, small-cell lung cancer, non-small cell lung cancer, bladder cancer, hepatocellular carcinoma, metastatic biliary tract cancer, diffuse large b-cell lymphoma, cutaneous t-cell lymphoma, peripheral t-cell lymphomas, ovarian cancer, prostate cancer, cholangiocarcinoma, gall bladder cancer and pancreatic cancer. It is a small molecule administered through oral and intravenous route. It acts by targeting polo-like kinase 1 (Plk1). Polo-like kinases play critical roles during multiple stages of cell cycle progression. Polo-like kinase (PLK) inhibitors targets the mitotic phase of the cell cycle. The drug candidate is based on genomic technology.

Cyclacel Pharmaceuticals overview

Cyclacel Pharmaceuticals (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, PLK inhibitor and CDK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. The company’s seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.

For a complete picture of Plogosertib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.